Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 3/20 | 0.71 |
| ▸ | TAAR1 | Q96RJ0 | 8/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.50 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | HRH1 | P35367 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7735333 | 0.85 | CALM1 (0.55) | HTR2ASMN1; SMN2LOXL2HPGD | |
| SCHEMBL14415701 | 0.85 | HTR2A (0.61) | HTR2ATAAR1SMN1; SMN2LOXL2CYP2A6 | |
| SCHEMBL16267990 | 0.84 | HTR2A (0.53) | HTR2ATAAR1SMN1; SMN2LOXL2CYP2A6 | |
| SCHEMBL1169208 | 0.84 | HTR2A (1.00) | HTR2ATAAR1SMN1; SMN2LOXL2CYP2A6 | |
| SCHEMBL18050877 | 0.81 | HTR2A (0.47) | HTR2ASMN1; SMN2LOXL2HPGD | |
| SCHEMBL14415699 | 0.81 | HTR2A (0.61) | HTR2ATAAR1SMN1; SMN2LOXL2CYP2A6 | |
| SCHEMBL10360527 | 0.81 | HTR2A (0.54) | HTR2ASMN1; SMN2LOXL2HPGD | |
| SCHEMBL7271489 | 0.76 | HTR2A (0.42) | HTR2ASMN1; SMN2HPGDHRH1 | |
| SCHEMBL8096435 | 0.76 | CALM1 (0.44) | HTR2ATAAR1HPGD | |
| SCHEMBL10601277 | 0.76 | TP53 (0.46) | HTR2ATAAR1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 173 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12036223-B2 | Small molecule trail gene induction by normal and tumor cells as an anticancer therapy | THE PENN STATE RESEARCH FOUNDATION (US) | 2024-07-16 | — | — | US | disclosed |
| EP-3679934-B1 | SMALL MOLECULE TRAIL GENE INDUCTION BY NORMAL AND TUMOR CELLS AS AN ANTICANCER THERAPY | PENN STATE RES FOUND (US) | 2024-06-05 | — | — | EP | disclosed |
| US-11951102-B2 | Methods and compositions for treating retina-associated disease using CCR3-inhibitors | ALKAHEST INC. (US) | 2024-04-09 | — | — | US | disclosed |
| WO-2024073282-A2 | HETEROCYCLES AS MODULATORS OF NSD ACTIVITY | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-04-04 | — | — | WO | disclosed |
| US-11931360-B2 | Compositions and methods relating to inhibitors of pro-inflammatory factors for treatment of cancer | WAYNE STATE UNIVERSITY (US) | 2024-03-19 | — | — | US | disclosed |
| US-20240082252-A1 | COMPOSITIONS AND METHODS RELATING TO CANCER | THE PENN STATE RESEARCH FOUNDATION | 2024-03-14 | — | — | US | disclosed |
| EP-4335511-A2 | SMALL MOLECULE TRAIL GENE INDUCTION BY NORMAL AND TUMOR CELLS AS AN ANTICANCER THERAPY | The Penn State Research Foundation (US) | 2024-03-13 | — | — | EP | disclosed |
| WO-2024031445-A1 | METHODS AND PROCESSES FOR THE PREPARATION OF MCT4 INHIBITORS | Vettore, LLC (US) | 2024-02-15 | — | — | WO | disclosed |
| US-20240024305-A1 | METHODS AND COMPOSITIONS FOR TREATING RETINA-ASSOCIATED DISEASE USING CCR3-INHIBITORS | ALKAHEST, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20230346764-A1 | Methods and Compositions for Treating Pruritus, Xerosis, and Associated Disease Using CCR3-Inhibitors | ALKAHEST, INC. | 2023-11-02 | — | — | US | disclosed |
| WO-2011005322-A2 | N-ALKOXYAMIDE CONJUGATES AS IMAGING AGENTS | LANTHEUS MEDICAL IMAGING, INC. (US) | 2011-01-13 | — | — | WO | disclosed |
| WO-2010115836-A1 | SUBSTITUTED PIPERIDINES AS CCR3 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-14 | — | — | WO | disclosed |
| CN-101686991-A | Compositions useful for reducing nephrotoxicity and methods of use thereof | VERROW PHARMACEUTICALS INC | 2010-03-31 | — | — | CN | disclosed |
| WO-2009148923-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-12-10 | — | — | WO | disclosed |
| WO-2009146347-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-12-03 | — | — | WO | disclosed |
| EP-1673088-A1 | 1,1,1- TRIFLUORO-4-PHENYL-4-METHYL-2-(1H-PYRROLO¬2,3-C|PYRIDIN-2-YLMETHYL)PENTAN-2-OL DERIVATIVES AND RELATED COMPOUNDS AS GLUCOCORTICOID LIGANDS FOR THE TREATMENT OF INFLAMMATORY DISEASES AND DIABETES | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2006-06-28 | — | — | EP | disclosed |
| WO-2005030213-A1 | 1,1,1-TRIFLUORO-4-PHENYL-4-METHYL-2-(1H-PYRROLO | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-04-07 | — | — | WO | disclosed |
| EP-1226146-A2 | QUINOLINE AND NAPHTHYRIDINE CARBOXYLIC ACID ANTIBACTERIALS | ABBOTT LABORATORIES (US) | 2002-07-31 | — | — | EP | disclosed |
| WO-2001057018-A1 | AZAAZULENE INHIBITORS OF P38 MAP KINASE AND TNF-ALPHA | ABBOTT LABORATORIES (US) | 2001-08-09 | — | — | WO | disclosed |
| WO-2001032655-A2 | QUINOLINE AND NAPHTHYRIDINE CARBOXYLIC ACID ANTIBACTERIALS | ABBOTT LABORATORIES (US) | 2001-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12036223-B2 | Small molecule trail gene induction by normal and tumor cells as an anticancer therapy | TSG101, TNFSF10, BCL2L10 | HTR2A 2155/4885TAAR1 3276/4885SMN1; SMN2 1225/4885 |
| US-11951102-B2 | Methods and compositions for treating retina-associated disease using CCR3-inhibitors | CCR3, CCR1, CCR4 | HTR2A 3808/4885TAAR1 981/4885SMN1; SMN2 527/4885 |
| US-20240082252-A1 | COMPOSITIONS AND METHODS RELATING TO CANCER | WEE1, WEE2, CHEK2 | HTR2A 4516/4885TAAR1 4683/4885SMN1; SMN2 4111/4885 |
| US-20230346764-A1 | Methods and Compositions for Treating Pruritus, Xerosis, and Associated Disease Using CCR3-Inhibitors | CCR3, CCR1, CCR4 | HTR2A 3594/4885TAAR1 2606/4885SMN1; SMN2 3606/4885 |
| US-20240024305-A1 | METHODS AND COMPOSITIONS FOR TREATING RETINA-ASSOCIATED DISEASE USING CCR3-INHIBITORS | CCR3, CCR1, CCR4 | HTR2A 3808/4885TAAR1 981/4885SMN1; SMN2 527/4885 |
| US-11931360-B2 | Compositions and methods relating to inhibitors of pro-inflammatory factors for treatment of cancer | LITAF, SERPINB1, RELA | HTR2A 4442/4885TAAR1 4439/4885SMN1; SMN2 4479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.